EMBC vs. IRTC, ICUI, IART, NVCR, UFPT, LMAT, ATEC, ATRC, MDXG, and AORT
Should you be buying Embecta stock or one of its competitors? The main competitors of Embecta include iRhythm Technologies (IRTC), ICU Medical (ICUI), Integra LifeSciences (IART), NovoCure (NVCR), UFP Technologies (UFPT), LeMaitre Vascular (LMAT), Alphatec (ATEC), AtriCure (ATRC), MiMedx Group (MDXG), and Artivion (AORT). These companies are all part of the "surgical & medical instruments" industry.
iRhythm Technologies (NASDAQ:IRTC) and Embecta (NASDAQ:EMBC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.
93.8% of Embecta shares are held by institutional investors. 0.7% of iRhythm Technologies shares are held by insiders. Comparatively, 0.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
iRhythm Technologies has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
iRhythm Technologies received 389 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 66.04% of users gave iRhythm Technologies an outperform vote while only 0.00% of users gave Embecta an outperform vote.
In the previous week, iRhythm Technologies had 4 more articles in the media than Embecta. MarketBeat recorded 5 mentions for iRhythm Technologies and 1 mentions for Embecta. iRhythm Technologies' average media sentiment score of 1.89 beat Embecta's score of 1.45 indicating that Embecta is being referred to more favorably in the news media.
Embecta has a net margin of 6.20% compared to Embecta's net margin of -25.33%. iRhythm Technologies' return on equity of -18.42% beat Embecta's return on equity.
Embecta has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
iRhythm Technologies presently has a consensus price target of $134.00, indicating a potential upside of 51.91%. Embecta has a consensus price target of $13.00, indicating a potential upside of 5.09%. Given Embecta's stronger consensus rating and higher probable upside, equities research analysts plainly believe iRhythm Technologies is more favorable than Embecta.
Summary
iRhythm Technologies and Embecta tied by winning 9 of the 18 factors compared between the two stocks.
Get Embecta News Delivered to You Automatically
Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
